Altre lingue Medivir AB

Azioni

MVIR B

SE0020181014

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 18:00:00 03/07/2024			Variaz. 5gg	Var. 1 gen.
2,89 ^SEK	-3,02%		-2,03%	+1,40%

27/06	Medivir AB presenta nuovi dati positivi dallo studio di Fostroxacitabina bralpamide (Fostrox) + Lenvima® nel carcinoma epatocellulare avanzato (HCC), attualmente in fase Ib / IIa.	CI
19/06	Medivir seleziona un partner CRO globale per l'imminente studio di fase 2B nell'HCC con fostrox + Lenvima e avvia la fattibilità dello studio	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Number of shares and votes in Medivir AB on 28 June 2024	28/06
BioStock: Medivir presents promising results in difficult-to-treat patient population	27/06
Medivir : Presentation	27/06
Fostrox + Lenvima® holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI	27/06
Medivir AB Presents Positive New Data from Its Ongoing Phase Ib / IIa Study of Fostroxacitabine Bralpamide + Lenvima® in Advanced Hepatocellular Carcinoma	27/06
Certain Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 20-JUN-2024.	20/06
Medivir selects global CRO partner for upcoming phase 2b study in HCC with fostrox + Lenvima and initiates study feasibility	19/06
Medivir Selects Global CRO Partner for Upcoming Phase 2B Study in HCC with fostrox + Lenvima and Initiates Study Feasibility	19/06
Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2024	30/05
Medivir to present at Redeye Growth Day	30/05
Medivir : acute;s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program	23/05
Medivir's licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program	23/05
Resolutions at the Annual General Meeting in Medivir on 7 May 2024	07/05
Medivir Aktiebolag Approves Board Appointments	07/05
BioStock: Double thumbs up for Medivir from the FDA	03/05
MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2024	30/04
Medivir AB Reports Earnings Results for the First Quarter Ended March 31, 2024	30/04
Medivir brings the Q1 webcast forward to 10 a.m. on April 30	29/04
Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI	29/04
Medivir AB Provides Update from Positive Type C Meeting with the FDA; Preparations for Enhanced Phase 2b in HCC with Fostrox + Lenvima	29/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Medivir AB

Azioni

MVIR B

SE0020181014

Altre lingue

Filtri